-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Xenon Pharmaceuticals (XENE) PT Raised to $56 at RBC Capital
-
RBC Capital Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE)
-
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
-
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Xenon Pharmaceuticals (XENE) prices upsized 8.46M share offering at $32.50
-
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
-
Xenon Pharmaceuticals (XENE) Announces $225M Proposed Public Offering
-
Xenon Pharmaceuticals Announces Proposed Public Offering
-
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
-
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
-
UPDATE: RBC Capital Starts Xenon Pharmaceuticals (XENE) at Outperform
-
Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh
-
Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
-
Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
-
Xenon Pharmaceuticals (XENE) Announces $250M Proposed Public Offering of Common Shares
-
Xenon Pharmaceuticals Announces Proposed Public Offering
-
Xenon Pharmaceuticals Announces Proposed Public Offering

